Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Voltaren lifts Novartis OTC internationally

You may also be interested in...



Food Safety And Rising Costs Top 2012 Challenges For Supplement Industry

Rising costs could lead to quality control problems in 2012 if consumers will not pay higher prices to cover manufacturers’ higher costs. Continued implementation of food safety reform “is a big deal,” partly because the requirements may be causing higher costs, says Loren Israelsen of the UNPA.

Food Safety And Rising Costs Top 2012 Challenges For Supplement Industry

Rising costs could lead to quality control problems in 2012 if consumers will not pay higher prices to cover manufacturers’ higher costs. Continued implementation of food safety reform “is a big deal,” partly because the requirements may be causing higher costs, says Loren Israelsen of the UNPA.

Sales & Earnings In Brief

MiraLAX, Zegerid lead Merck OTCs

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS105195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel